+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 54 Pages
  • December 2024
  • GlobalData
  • ID: 1315546
Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise Pollen, Moulds, Arthropods, Epithelia and others. It has an operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK, among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc Key Recent Developments

  • Nov 06, 2024: Allergy Therapeutics: Audited Preliminary Results for the Year Ended 30 June 2024
  • Oct 01, 2024: Allergy Therapeutics : Update on Funding and Preliminary Results
  • Jun 27, 2024: Allergy Therapeutics Announces Appointment of David Ball as Non-Executive Director
  • Jun 27, 2024: Allergy Therapeutics Announces Appointment of Non-Executive Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Allergy Therapeutics Plc - Key Facts
  • Allergy Therapeutics Plc - Key Employees
  • Allergy Therapeutics Plc - Key Employee Biographies
  • Allergy Therapeutics Plc - Major Products and Services
  • Allergy Therapeutics Plc - History
  • Allergy Therapeutics Plc - Company Statement
  • Allergy Therapeutics Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Allergy Therapeutics Plc - Business Description
  • Geographical Segment: Central Europe
  • Target Markets
  • Performance
  • Geographical Segment: Rest of World (including UK)
  • Performance
  • Geographical Segment: Southern Europe
  • Target Markets
  • Performance
  • R&D Overview
  • Allergy Therapeutics Plc - Corporate Strategy
  • Allergy Therapeutics Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Allergy Therapeutics Plc - Strengths
  • Allergy Therapeutics Plc - Weaknesses
  • Allergy Therapeutics Plc - Opportunities
  • Allergy Therapeutics Plc - Threats
  • Allergy Therapeutics Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Allergy Therapeutics Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 06, 2024: Allergy Therapeutics: Audited Preliminary Results for the Year Ended 30 June 2024
  • Oct 01, 2024: Allergy Therapeutics : Update on Funding and Preliminary Results
  • Jun 27, 2024: Allergy Therapeutics Announces Appointment of David Ball as Non-Executive Director
  • Jun 27, 2024: Allergy Therapeutics Announces Appointment of Non-Executive Director
  • Apr 03, 2024: Allergy Therapeutics : Director Resignation
  • Mar 27, 2024: Allergy Therapeutics PLC Interim Results for six months ended 31 Dec 2023
  • Mar 11, 2024: Allergy Therapeutics PLC Appointment of Shaun Furlong to Board of Directors
  • Sep 27, 2023: Allergy Therapeutics : Unaudited Preliminary Results for the Year Ended 30 June 2023
  • Aug 10, 2023: Allergy Therapeutics : Trading update for the year ended 30 June 2023
  • Apr 06, 2023: Allergy Therapeutics : Trading and business update and update on annual report and accounts
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Allergy Therapeutics Plc, Key Facts
  • Allergy Therapeutics Plc, Key Employees
  • Allergy Therapeutics Plc, Key Employee Biographies
  • Allergy Therapeutics Plc, Major Products and Services
  • Allergy Therapeutics Plc, History
  • Allergy Therapeutics Plc, Subsidiaries
  • Allergy Therapeutics Plc, Key Competitors
  • Allergy Therapeutics Plc, Ratios based on current share price
  • Allergy Therapeutics Plc, Annual Ratios
  • Allergy Therapeutics Plc, Interim Ratios
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Allergy Therapeutics Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Allergy Therapeutics Plc, Performance Chart (2020 - 2024)
  • Allergy Therapeutics Plc, Ratio Charts
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergopharma GmbH & Co KG
  • Stallergenes Greer Ltd
  • Roxall Medizin GmbH
  • Laboratorios LETI SLU
  • Biomay AG
  • HAL Allergy BV